Pfizer Inc. $PFE Shares Purchased by ABN Amro Investment Solutions

ABN Amro Investment Solutions lifted its holdings in shares of Pfizer Inc. (NYSE:PFE) by 11.9% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 313,794 shares of the biopharmaceutical company’s stock after purchasing an additional 33,262 shares during the quarter. ABN Amro Investment Solutions’ holdings in Pfizer were worth $8,811,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Evolution Wealth Management Inc. grew its position in Pfizer by 132.2% during the first quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 566 shares during the period. Horizon Financial Services LLC increased its position in Pfizer by 174.8% during the 4th quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 645 shares in the last quarter. Godfrey Financial Associates Inc. purchased a new position in Pfizer in the fourth quarter valued at approximately $26,000. YANKCOM Partnership purchased a new position in Pfizer in the fourth quarter valued at approximately $28,000. Finally, HFM Investment Advisors LLC grew its stake in Pfizer by 61.0% during the fourth quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock worth $28,000 after buying an additional 427 shares during the period. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer’s TALZENNA plus XTANDI combination received FDA Priority Review for men with HRR gene-altered metastatic castration-sensitive prostate cancer, which could expand the drug pair’s approved use and support oncology revenue growth if approved. Article Title
• Positive Sentiment: Some commentary highlights Pfizer as an undervalued healthcare name, suggesting investors may be overlooking its earnings power and pipeline optionality. Article Title
• Neutral Sentiment: Analysts are also watching Pfizer’s non-oncology portfolio this earnings season, with expected strength in Eliquis and Vyndaqel offset by continued weakness in COVID-related products. Article Title
• Negative Sentiment: Pfizer is facing expanded patent litigation tied to mRNA lipid nanoparticle technology, adding legal uncertainty around its COVID-19 vaccine business and creating a potential overhang on sentiment. Article Title
• Negative Sentiment: Broader U.S. drug-policy headlines, including proposed tariffs on generic medicines, may keep pressure on the pharmaceutical sector even though the direct impact on Pfizer is less clear than for generic-focused peers. Article Title

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on PFE shares. Citigroup raised their target price on shares of Pfizer from $26.00 to $27.00 and gave the company a “neutral” rating in a research note on Wednesday, April 29th. Morgan Stanley raised their price objective on Pfizer from $27.00 to $28.00 and gave the company an “equal weight” rating in a research report on Friday, April 10th. Bank of America decreased their target price on Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a research report on Friday, July 10th. JPMorgan Chase & Co. lowered their target price on Pfizer from $30.00 to $28.00 and set a “neutral” rating for the company in a research note on Wednesday, July 8th. Finally, Royal Bank Of Canada upgraded Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 price target for the company in a report on Tuesday, June 9th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $28.50.

Pfizer Stock Performance

NYSE:PFE opened at $24.84 on Thursday. The firm has a 50-day moving average of $25.14 and a two-hundred day moving average of $26.18. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.25 and a quick ratio of 0.94. The stock has a market cap of $141.60 billion, a P/E ratio of 18.97 and a beta of 0.35. Pfizer Inc. has a 1-year low of $23.11 and a 1-year high of $28.75.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.72 by $0.03. The business had revenue of $14.45 billion for the quarter, compared to analyst estimates of $13.84 billion. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The company’s revenue for the quarter was up 5.4% compared to the same quarter last year. During the same period in the previous year, the company earned $0.92 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, research analysts expect that Pfizer Inc. will post 2.96 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.9%. The ex-dividend date is Friday, July 24th. Pfizer’s dividend payout ratio is 131.30%.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.